Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

NCT01288911 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01288911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01288911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
March 22, 2011
Completion date
November 8, 2017
Enrollment
375 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms